2020 The Journal of the National Comprehensive Cancer Network  
The NCCN Oncology Research Program (ORP) recently announced 4 projects selected to receive funding for clinical and preclinical evaluation of futibatinib (TAS-120). Futibatinib is an oral, irreversible, selective fibroblast growth factor receptor (FGFR) 1-4 inhibitor. In a phase I dose-escalation trial, futibatinib demonstrated tolerability, pharmacodynamic activity, and preliminary antitumor activity in heavily pretreated patients with advanced solid tumors. 1 NCCN will provide study oversight
more » ... ide study oversight while Taiho Oncology is providing drug and funding. The following projects were selected following formal scientific evaluation by a panel of NCCN experts: • Phase Ib trial of Olaparib in Combination with Futibatinib in All Solid "This is a really exciting time for such research," said Wui-Jin Koh, MD, Chief Medical Officer, NCCN. "There have been some recent discoveries on how FGFR aberrations can impact tumor progression and survival in patients with different cancers, with endometrial cancer being one example.
doi:10.6004/jnccn.2020.0046 fatcat:sbe3zdqinngmrldjicmzdv2noy